Laretol Capsule contains Calcitriol 0.25 mcg, an active metabolite of vitamin D3, essential for calcium homeostasis and bone metabolism. It is primarily indicated for the treatment of conditions associated with hypocalcemia, such as hypoparathyroidism, and for managing secondary hyperparathyroidism in patients with chronic renal failure undergoing dialysis. Calcitriol facilitates intestinal absorption of calcium and phosphate, thereby aiding in the maintenance of adequate serum calcium levels and promoting normal bone mineralization. Laretol is also utilized in the management of metabolic bone diseases like osteoporosis and rickets where vitamin D deficiency is implicated. The capsule formulation ensures convenient oral administration and optimal bioavailability. Dosage should be individualized based on the patient’s serum calcium levels and clinical response, with careful monitoring to avoid hypercalcemia and hypercalciuria, which may lead to adverse effects such as nephrolithiasis or vascular calcification. Contraindications include hypercalcemia, vitamin D toxicity, and hypersensitivity to any component of the formulation. Patients should be advised to maintain regular follow-up and laboratory assessments during therapy. Laretol Capsule should be used under medical supervision, particularly in patients with renal impairment, to ensure safe and effective treatment outcomes.